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Clinical diagnosis of grade 1 acute graft-versus-host disease (GVHD) marks the beginning of a potentially
progressive and fatal course of GVHD after hematopoietic stem cell transplantation (HSCT). However, inter-
ventional studies to treat early GVHD are lacking. We conducted a single-arm prospective phase II trial to test
the hypothesis that treatment of newly diagnosed grade 1 acute GVHD with etanercept and topical corti-
costeroids would reduce progression to grade 2 to 4 within 28 days. Study patients (n ¼ 34) had a median age
of 51 years (range, 10 to 67 years) and had undergone unrelated (n ¼ 22) or related (n ¼ 12) donor HSCT.
Study patients were treated with etanercept (.4 mg/kg, maximum 25 mg/dose) twice weekly for 4 to 8 weeks.
Ten of 34 patients (29%) progressed to grade 2 to 4 acute GVHD within 28 days. The cumulative incidence of
grade 2 to 4 and grade 3 to 4 acute GVHD at 1 year was 41% and 3%, respectively. Nonrelapse mortality was
19% and overall survival was 63% at 2 years. Among a contemporaneous control cohort of patients who were
diagnosed with grade 1 acute GVHD and treated with topical corticosteroids but not etanercept during the
study period, 12 of 28 patients (43%) progressed to grade 2 to 4 GVHD within 28 days, with a 1-year incidence
of grade 2 to 4 GVHD and grade 3 to 4 GVHD of 61% (41% versus 61%, P ¼ .08) and 18% (3% versus 18%, P ¼ .05),
respectively. Patients treated with etanercept also experienced less increase in GVHD plasma biomarkers
suppression of tumorigenicity 2 (P ¼ .06) and regenerating islet-derived 3-alpha (P ¼ .01) 28 days after grade
1 acute GVHD diagnosis compared with contemporaneous control patients. This study was terminated early
because of poor accrual. Future prospective studies are needed to identify patients with grade 1 acute GVHD
at risk of swift progression to more severe GVHD and to establish consensus for the treatment of grade 1 acute
GVHD. This trial is registered with ClinicalTrials.gov, number NCT00726375.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is an important therapy for many malignant and
nonmalignant conditions [1]. A signiﬁcant barrier to the
more widespread application of HSCT is the potentially se-
vere and fatal complication of acute graft-versus-hostedgments on page 1433.
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14.05.023disease (GVHD) [2]. Although prophylaxis strategies have
lowered the risk of life-threatening GVHD, 40% to 70% of
patients are still at risk of developing the complication [3-
7]. Moreover, in these patients, treatment approaches have
provided inconsistent outcomes [8]. High-dose systemic
corticosteroids remain the standard initial therapy for grade
2 to 4 acute GVHD, yet they carry signiﬁcant risks [9], and
complete response rates range from 25% to 40% [10-13].
Patients who do not have at least a partial response to
therapy within the ﬁrst 28 days are at high risk for non-
relapse mortality (NRM) 6 months from the onset of therapy
[14-17].Transplantation.
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acute GVHD is topical corticosteroid therapy [9]. However, in
clinical practice, it is likely that far more patients with grade
1 acute GVHD are treated with systemic corticosteroids than
are reported. In a recent multicenter Blood and Marrow
Transplant Clinical Trials Network phase II trial, up to 13% of
study patients had a clinical diagnosis of grade 1 acute GVHD
and were treated with systemic steroids in conjunction with
a secondary agent [18]. Nonetheless, to our knowledge,
interventional studies targeted at treatment of grade 1 acute
GVHD have not been previously reported.We reasoned that a
strategy allowing early, standardized treatment of grade 1
acute GVHD would reduce progression in the ﬁrst 28 days of
diagnosis.
TNF-alpha (TNFa) is an important component of the in-
ﬂammatory cascade that evolves into acute GVHD [19-22].
Our group has previously shown that the magnitude of in-
crease in TNF-receptor-1 (TNFR1), a surrogate for TNFa,
7 days after HSCT relative to pre-HSCT baseline levels,
strongly correlates with increased GVHD incidence, NRM,
and decreased overall survival (OS) in adults and children
[19,20]. Etanercept, a recombinant human soluble TNFa re-
ceptor fusion protein, competes for TNFa binding and ren-
ders it inactive [23]. Etanercept attenuated rising TNFR1
levels early after HSCT in patients who received nonetotal
body irradiation conditioning and correlated with good
clinical outcomes when used in combination with standard
immunosuppression for GVHD prophylaxis [24]. Based on
preclinical and clinical studies implicating a role for TNF-a in
the etiology of acute GVHD [19-22,24], we hypothesized that
TNF-a blockade with etanercept for treatment of grade 1
acute GVHD would reduce the progression to grade 2 to 4
within 28 days.SUBJECTS AND METHODS
Study Cohort
A prospective, open-label, single-arm phase II trial of etanercept com-
bined with topical corticosteroid therapy for grade 1 acute GVHD after
allogeneic HSCT was conducted between May 2008 and April 2013. Patients
with a clinical diagnosis of grade 1 acute GVHD (stage 1 or 2 skin rash
covering <50% body surface area) were eligible for inclusion in the study if
sufﬁcient rash were present to biopsy and the results were consistent with
the clinical diagnosis of GVHD. Patients of any age who underwent HSCT
with donor cells from any source after either a myeloablative or non-
myeloablative preparative regimen and with clinical grade 1 acute GVHD
were eligible. Patients with grade 2 to 4 acute GVHD or with an active
infection unresponsive to antibiotics were ineligible for this study. Patients
who used systemic steroids at any previous time for treatment of GVHD and
patients who received etanercept for any other purpose were also ineligible.
The protocol and informed consents were approved by the institutional
review board at the University of Michigan. All patients and their legal
guardians signed informed consents in accordance with the Declaration of
Helsinki.
The GVHD prophylaxis regimens consisted of tacrolimus initiated on
day -3 beforeHSCT (titrated andmaintained at a level of 8 to 12 ng/mL) either
withmini-methotrexate administered at a dose of 5mg/m2 i.v. on days 1, 3, 6,
and 11 after HSCT or with mycophenolate mofetil at 10 mg/kg/dose every
8hours ondays0 through28. In the absenceofGVHD, tacrolimuswas tapered
starting from day 56 after HSCT and was discontinued by day 180.
Supportive care therapies were administered according to institutional
clinical practice guidelines. Antimicrobial prophylaxis included levoﬂoxacin
500 mg once daily for prevention of bacterial infections, voriconazole
200 mg twice daily, acyclovir 400 mg twice daily for viral prophylaxis, and
sulfamethoxazole/trimethoprim or pentamidine for prevention of Pneu-
mocystis carinii pneumonia. Pediatric patients received age and/or weight
equivalent dosing of antibiotics. Cytomegalovirus (CMV) DNA was moni-
toredweekly by quantitative PCR [25] and preemptive therapywith antiviral
agents was begun in the event of a positive assay. Intravenous immu-
noglobulin (Ig) replacement therapy (400 mg/kg) was given for IgG
levels <400 mg/dL.Infection
Infections were enumerated for each patient for 180 days, beginning on
the ﬁrst day of etanercept treatment. An infection was deﬁned using the
following criteria: 1 or more positive blood and/or ﬂuid cultures or the
detection of DNA in the plasma by quantitative PCR. Proven, probable, and
possible invasive fungal infections were classiﬁed according to international
consensus criteria [26].
GVHD Treatment
All study patients were treated with topical corticosteroids (.1% triam-
cinolone cream applied to affected areas 3 times daily) at the time of grade 1
acute GVHD diagnosis, according to institutional clinical practice guidelines.
Etanercept (.4 mg/kg, maximum 25 mg/dose) was administered subcuta-
neously twice weekly on nonconsecutive days for 4 weeks, as previously
reported at our center [20], for a total of 8 doses. In some patients, eta-
nercept was continued for an additional 4 weeks, as described below. Doses
were held and not replaced in patients with bacteremia, hemodynamic
instability, fever, or persistent viral infection. If signs and symptoms of
infection resolved (blood pressure stable, negative blood cultures for a
minimum of 48 hours, 50% reduction in viral copy number) before needing
to hold a third consecutive dose of trial drug, etanercept dosing was
resumed and the patient was allowed to continue on the trial. In patients
who progressed to grade 2 to 4 acute GVHD, standard high-dose systemic
corticosteroid therapy was initiated and etanercept was permanently
discontinued.
GVHD Scoring and Evaluation of Response
GVHD was monitored weekly in all patients using the modiﬁed
Glucksberg criteria [27]. Formal GVHD grading to evaluate response in all
patients was performed at the start of etanercept treatment (day 0 of trial),
week 4, and week 8. Overall GVHD grade was used to determine the
response. A complete response (CR) was deﬁned as the complete resolution of
all manifestations of GVHD (all organs grade 0). Patients achieving a CR at
4 weeks stopped etanercept treatment (8 total doses). Patients with no
change in overall grade of GVHD (stable disease, SD) at 4 weeks received 4
additional weeks of etanercept treatment (16 total doses). Treatment success
was deﬁned as having CR or SD at the 4-week assessment (ie, no systemic
corticosteroid therapy). Treatment failure was deﬁned as progression to
grade 2 to 4 acute GVHDwithin the ﬁrst 4 weeks of etanercept treatment. All
patients, including treatment failures, were re-evaluated for GVHD grade
and response at 8 weeks. Chronic GVHD was diagnosed and staged ac-
cording to published criteria [28] and treated according to institutional
clinical practice guidelines.
Comparison with a Contemporaneous Control Cohort
A contemporaneous control cohort was constructed from the Blood and
Marrow Transplantation Program Clinical Database to provide a comparator
for the study patients, given a lack of published data on clinical outcomes
associated with grade 1 acute GVHD and its treatment. The contempora-
neous control cohort comprises all patients who underwent HSCT according
to study criteria and were diagnosed with grade 1 acute GVHD during the
same time interval as the study patients (2008 to 2013) but who chose not to
enroll in the study (n ¼ 28). All contemporaneous control patients were
treated with topical corticosteroids (.1% triamcinolone cream applied to
affected areas 3 times daily) at the time of grade 1 acute GVHD diagnosis,
according to institutional clinical practice guidelines. GVHD was monitored
weekly using the modiﬁed Glucksberg criteria [27] and standard high-dose
systemic corticosteroid therapy was initiated in patients who progressed to
grade 2 to 4 acute GVHD.
Correlative Studies: Plasma Biomarkers
Peripheral blood samples were collected on the day of clinical grade 1
GVHD diagnosis and 14 and 28 days thereafter. Plasma was obtained after
Ficoll (Amersham, Piscataway, NJ) gradient centrifugation on the day of
collection. Samples were dispensed without additives into cryovials and
frozen at 80C for later analysis. Suppression of tumorigenicity 2 (ST2),
regenerating islet-derived 3-alpha (Reg3a), TNFR1, and elaﬁn concentra-
tions in each plasma sample were determined using an enzyme-linked
immunosorbant assay (ELISA) as previously described [20,24,29-31]. Day-
28 biomarker levels were compared between study and contemporaneous
control patients after normalizing to day 0 levels (ie, ratio of day 28 over day
0 concentration) for each patient. The normalized value thus indicates the
fold change in biomarker concentration from day 0 to day 28. Samples and
standards were run in duplicate. Absorbance was measured using a Synergy
HT plate reader (BioTek Instruments, Winooski, VT) and results were
calculated using Gen 5.1 software (BioTek Instruments). Assays were per-
formed at the Immunologic Monitoring Core of the University of Michigan
Cancer Center.
Table 1
Baseline Demographics and Clinical Characteristics of the Study Participants
and Controls
Characteristic Study Control P Value
Age, yr 51 (30) 56 (12) .10
Gender
Male 26 (76) 18 (64) .44
Female 8 (24) 10 (36)
Race/ethnicity
White 30 (88) 24 (86) .54
Black or African American - 1 (4)
Other* 4 (12) 3 (11)
Diagnosis
Malignant 32 (94) 28 (100) .56
Acute myelogenous leukemia 13 (38) 8 (29)
Acute lymphoblastic leukemia 6 (18) 7 (25)
Multiple myeloma 4 (12) 2 (7)
Myelodysplastic syndrome 4 (12) 3 (11)
Non-Hodgkin’s lymphoma 2 (6) 4 (14)
Myeloﬁbrosis 2 (6) 1 (4)
Chronic lymphocytic leukemia 1 (3) 2 (7)
Chronic myelogenous leukemia - 1 (4)
Nonmalignant disease 2 (6) -
Disease risk status
Low 13 (38) 11 (39) .74
Intermediate 5 (15) 6 (21)
High 16 (47) 11 (39)
Donor
Matched related 12 (35) 10 (36) .46
Matched unrelated 16 (47) 12 (43)
Mismatched related - 2 (7)
Mismatched unrelated 6 (18) 4 (14)
CMV status
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This trial was designed to enroll 50 patients to have sufﬁcient power
(90%) to detect a decrease in the percentage of patients who progressed
within 4 weeks of initiation of treatment for grade 1 acute GVHD, from 58%
observed historically between 2001 and 2006 at the University of Michigan
Medical Center to 38%, assuming a type 1 error rate of 5%. At the time of
study design in 2007 and 2008, grade 1 acute GVHD was diagnosed in
approximately 21 patients per year at the University of Michigan. Assuming
80% of patients would be eligible and consent to study participation, we
expected accrual to take approximately 3 years. However, because of
competing studies at our center and unforeseen difﬁculties obtaining
approval for insurance coverage of the study drug, we accrued a total of 34
patients over a 5-year period (2008 to 2013). Based solely on the slow
accrual of the study, the decision was made by the blood and marrow
transplantation team, in concert with recommendations provided by the
University of Michigan Comprehensive Cancer Center Data Safety Moni-
toring Board, to terminate the study early. Herein, we report the ﬁndings in
34 subjects. All subjects who enrolled in the study and received at least 1
dose of etanercept were included in the analysis.
OS was measured from the date of transplantation to the earlier of death
from any cause or end of follow-up and was estimated with the methods of
Kaplan-Meier [32]. The cumulative incidence of relapse, NRM, grade 2 or
higher acute GVHD, and chronic GVHD were estimated using the method of
Fine and Gray [33]. Relapse and NRM were competing risks for each other
and relapse and death were competing risks for acute and chronic GVHD.
Baseline characteristics were compared between the study and contempo-
raneous control cohorts with the use of the Wilcoxon rank-sum test for
continuous variables and chi-square or Fisher exact tests for categorical
characteristics. Concentrations of biomarker proteins in plasma samples
were compared using theWilcoxon rank-sum test. These statistical analyses
were performed in R (R Project for Statistical Computing at www.r-project.
org) and GraphPad Prism 6.0 (GraphPad Software, Inc. La Jolla, CA). A 2-sided
P value less than .05 was considered to indicate statistical signiﬁcance. This
trial is registered with clinicaltrials.gov, number NCT00726375.Recipient (R) or donor (D) positive 24 (71) 20 (71) .80
Rþ, Dþ 9 (26) 10 (36)
Rþ, D 12 (35) 9 (32)
R, Dþ 3 (9) 1 (4)
Recipient and donor negative 10 (29) 8 (29)
Conditioning
Full 24 (71) 21 (76) .92
Busulfan-basedy 20 (59) 18 (65)
TBI-basedz 3 (9) 3 (11)
BCNU-basedx 1 (3) -
Reduced 10 (30) 7 (25)
Fludarabine, busulfan 6 (18) 6 (21)
Fludarabine, melphalan 3 (9) 1 (4)
Cyclophosphamide, ATG 1 (3) -
CD34þ count,  106 cells/kg 6.3 (2.2) 5.7 (1.2) .36
GVHD prophylaxis
Calcineurin inhibitor, MTX 18 (53) 13 (46) .80
Calcineurin inhibitor, MMF 16 (47) 15 (54)
Time HSCT to grade 1 acute
GVHD diagnosis, d
28 (35) 32 (19) .84
Time to progression, grade 1
to grade 2-4 GVHD, d
24 (50) 7 (27) .08
BCNU indicates carmustine; ATG, antithymocyte globulin; MTX, mini-
methotrexate; MMF, mycophenolate mofetil.
Data presented are n (%) or median (interquartile range).
* Study: Asian (n ¼ 1), Hispanic or Latino (n ¼ 3); Control: American In-
dian/Alaskan Native (n ¼ 1), Hispanic or Latino (n ¼ 2).
y Study: ﬂudarabine and busulfan (n ¼ 14), clofarabine and busulfan
(n¼ 6); Control: ﬂudarabine and busulfan (n¼ 10), clofarabine and busulfan
(n ¼ 8).
z Study: cyclophosphamide and TBI (n ¼ 1), thiotepa, cyclophosphamide
and TBI (n ¼ 1), campath, ﬂudarabine, cyclophosphamide and TBI (n ¼ 1);
Control: cyclophosphamide and TBI (n ¼ 3).
x Study: rituximab, carmustine, etoposide, cytarabine, and melphalan
(n ¼ 1).RESULTS
Patient Characteristics
A total of 34 patients were enrolled in this phase II trial
and received treatment with etanercept for newly diagnosed
grade 1 acute GVHD (May 2008 to April 2013). Sixteen pa-
tients received a full-course of etanercept treatment (8 doses
over 4 weeks). Seven patients received 2 courses of eta-
nercept (15 to 16 doses over 8 weeks). Eleven patients
received less than a full course of treatment because of early
removal from the study as a result of GVHD progression
(n ¼ 8), development of idiopathic pneumonia syndrome
(IPS, n ¼ 1) or having missed 2 consecutive doses because
of viral infection (n ¼ 2).
Patient demographics and clinical characteristics are
summarized in Table 1. The median age was 51 years (range,
10 to 67 years). Sixty-two percent of patients had
intermediate-to-high disease risk status, classiﬁed according
to the American Society of Blood and Marrow Trans-
plantation 2013 disease classiﬁcation index [34]. Twelve
patients received HLA-matched related grafts and 16 pa-
tients received matched unrelated grafts. Four patients
received 1 locus HLA-mismatched grafts from unrelated
donors and 2 patients received unrelated double cord grafts
mismatched at 2 loci. Twenty-four patients (71%) received
myeloablative conditioning. These regimens were busulfan-
based (12.8 mg/kg; n ¼ 20), total body irradiationebased
(1200 cGy; n ¼ 3), or BCNU-based (carmustine, 300 mg/m2;
n ¼ 1). Ten patients received reduced-intensity conditioning
regimens consisting of ﬂudarabine and busulfan (ﬂudar-
abine, 120 mg/m2; busulfan, 6.4 mg/kg; n ¼ 6), ﬂudarabine
andmelphalan (ﬂudarabine, 120mg/m2; melphalan, 140mg/
m2; n¼ 3), or cyclophosphamide and antithymocyte globulin
(cyclophosphamide, 200 mg/kg; Thymoglobulin (Genzyme,
Cambridge, MA), 7.5 mg/kg; n ¼ 1). All patients received
standard GVHD prophylaxis with a calcineurin inhibitor andmini-methotrexate (n ¼ 18) or mycophenolate mofetil
(n ¼ 16) after transplantation.
Safety and Infection
The safe use of etanercept in patients after HSCT has been
demonstrated at our institution previously [11,18,24]. Treat-
ment with etanercept in this study was well tolerated. There
Table 2
Infections
Category Total Day 0-59* Day 60-180 Organisms
Study Cohort
Gram-positive bacteria 5 3 2 Coagulase negative Staphylococcus sp., Bacillus sp., Mycobacterium gordonae,
Enterococcus faecium
Gram-negative bacteria 3 1 2 Escherichia coli, Klebsiella oxytoca, Enterobacter cloacae
Viral 18 11 7 CMV, HHV-6, HSV-1, RSV, EBV, Human adenovirus
Fungal 1 1y - Rhizopus sp.
Polymicrobial 2 2 - 1 patient: gram positive a Streptococcus sp., Rhodococcus gordonia and coagulase
negative Staphylococcus sp.; 1 patient: HHV-6 and gram positive a Streptococcus sp.
Total events 29 18 11
Alive at interval start n ¼ 34 n ¼ 34 n ¼ 33
Contemporaneous Cohort
Gram-positive bacteria 9 2 7 Coagulase negative Staphylococcus sp., Lactobacillus sp., Enterococcus faecium,
aerobic gram positive rod NOS, Nocardia asteroides, Streptococcus pneumoniae
Gram-negative bacteria 1 1 - Klebsiella pneumoniae
Viral 12 8 4 CMV, HHV-6, RSV, EBV
Fungal 3 - 3z Rhizopus sp., Aspergillus fumigatus
Polymicrobial 2 - 2 1 patient: gram positive coagulase negative Staphylococcus sp., gram negative
Sphingomonas paucimobilis and Stenotrophomonas maltophilia; 1 patient:
CMV and HSV-1.
Total events 27 11 16
Alive at interval start n ¼ 28 n ¼ 28 n ¼ 26
Sp indicates species; HHV6, Human herpesvirus 6; HSV1, Herpes simplex virus 1; RSV, Human respiratory syncytial virus; EBV, Epstein-Barr virus; NOS, not
otherwise speciﬁed.
Listed are the counts of new infection events during the 180 days from the start of etanercept treatment (study cohort) or grade 1 GVHD diagnosis (contem-
poraneous control cohort) and the count by interval within these 180 days. Patients with polymicrobial infections (concurrent infection by >1 organism)
received a single infection count, unless otherwise speciﬁed. In addition to the count of events, the table shows the count of patients alive (n) at the start of each
interval. Organisms not captured include enterococci from stool, rectum, skin; Clostridium difﬁcile from stool; BK virus from urine; and oral thrush.
* Etanercept treatment duration was 28 or 56 days.
y Concomitant coagulase negative Staphylococcus sp. infection, thought to be a contaminant, counted as a separate Gram-positive event.
z Concomitant Streptococcus pneumonia infection in 1 patient, counted as a separate Gram-positive event.
Grade 1 acute GVHD
(skin grade 1-2 only)
Intervention: Etanercept 
(2 times/wk x 4 wk)
n=34
Progression < 4 wks
= Study Failure
Start systemic steroids
n=10
4wk: Evaluate GVHD
CR
n=14
Stop Etanercept
SD
n=10
Continue Etanercept
CR
n=5
SD
n=2
PD
n=2
4wk: Evaluate GVHD*
8wk: Evaluate GVHD 8wk: Evaluate GVHD
Figure 1. Study schema. Thirty-four patients diagnosed with skin grade 1 to 2
acute GVHD (overall grade 1) were treated with etanercept twice weekly for
4 weeks. Patients whose GVHD progressed to grade 2 to 4 within the ﬁrst
28 days were considered study failures. In these patients, etanercept therapy
was stopped and treatment with systemic steroids was initiated. GVHD was
formally evaluated 4 and 8 weeks after diagnosis and onset of etanercept
therapy. CR indicates complete resolution of GVHD; SD, stable disease; PD,
progressive disease. *One patient died of idiopathic pneumonia syndrome
(IPS) before the 4 week GVHD evaluation; ySeven of 10 patients with SD at the
4-week evaluation received an additional 4-week course of etanercept
treatment.
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etanercept. Etanercept was discontinued early in 2 patients
whose treatment was held according to study design, and
whose viral infection (respiratory syncytial virus, CMV) did
not adequately resolve before the third consecutive dose was
held.
Infections were monitored for 180 days, beginning at the
onset of etanercept treatment. Viral reactivations were the
most common type of infection observed in study patients.
Twelve patients developed a total of 18 viral reactivations; 11
were CMV reactivations. Therewere 7 cases of Gram-positive
bacteremia (5 single organism and 2 polymicrobial in-
fections) and 3 cases of Gram-negative bacteremia in study
patients. Bacterial pneumonia accounted for 1 death, which
occurred 13 weeks after etanercept treatment. One patient
developed fatal invasive fungal infection 12 weeks after
etanercept. Both fatal infections occurred during treatment
with systemic corticosteroids for progressive acute GVHD. A
complete list of bacterial, viral, and fungal infections, and
time to their development, are listed in Table 2. The number
and severity of infectious complications were consistent
with the patient population and were not different from the
incidence of infection in the contemporaneous control
cohort, who did not receive etanercept.
Acute GVHD
The median time to onset of grade 1 acute GVHD in study
patients was 28 days (range, 7 to 235 days) after HSCT
(Table 1). We hypothesized that treatment of grade 1 acute
GVHD with etanercept would reduce the proportion of pa-
tients who progressed to grade 2 to 4 acute GVHD within
4 weeks of diagnosis from 58%, historically observed at our
institution, to 38%. Etanercept limited the progression to
grade 2 to 4 GVHDwithin 4weeks of grade 1 GVHD diagnosis
(ie, study failure) to 10 of 34 patients (29%) (Figure 1).Fourteen (41%) of the study patients achieved a CR at
4 weeks, and 10 patients (29%) had SD after etanercept and
topical corticosteroid treatment. Of the 10 patients who
failed etanercept treatment and started systemic cortico-
steroid therapy, 5 (50%) and 2 (20%) achieved CR and SD,
respectively, by 4 weeks. In the remaining 3 patients who
la
tiv
e 
In
ci
de
nc
e
0.
4
0.
6
0.
8
1.
0
 GVHD
Grade 2-4
A
E. Gatza et al. / Biol Blood Marrow Transplant 20 (2014) 1426e14341430failed etanercept therapy, 2 (20%) developed progressive
GVHD by 4 weeks but achieved CR by 8 weeks; 1 developed
IPS after 2 doses of etanercept and died.
The cumulative incidence of grade 2 to 4 acute GVHD at
1 year was 41%, with a median time of onset of 24 days
(range, 2 to 352 days) after grade 1 GVHD diagnosis
(Figure 2A, Table 1). Only 1 study patient developed overall
grade 3 to 4 acute GVHD, resulting in a cumulative incidence
at 1 year of 3% (Figure 2A). This patient developed grade 3
gastrointestinal (GI) GVHD (grade 3 overall GVHD) 3 days
after grade 1 acute GVHD diagnosis and after a single dose of
etanercept.Months Since Transplant
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The 2-year cumulative incidence of relapse was 32%, with
a median time from HSCT to relapse of 251 days (range, 73 to
854). All-cause 2-year NRM was 19% (Figure 2B) and acute
GVHD-related mortality was 13%. The causes of NRM were
GVHD-related complications (n ¼ 3), IPS (n ¼ 1), and a car-
diac event unrelated to GVHD (n¼ 1). With a median follow-
up of 20 months (range, 3.6 to 63.4 months), overall 2-year
survival was 63% (Figure 2C).Months Since Transplant
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Figure 2. Incidence of acute GVHD, NRM, and OS in study patients (n ¼ 34).
(A) 1-year cumulative incidence of acute GVHD. Dashed line, grade 2 to 4
acute GVHD; solid line, grade 3 to 4 acute GVHD. (B) 2-year NRM. (C) 2-
year OS.Comparison with Contemporaneous Controls
Patients diagnosed with grade 1 acute GVHD in the
contemporaneous control cohort were treated with topical
corticosteroids. Baseline clinical characteristics of the control
cohort are reported in Table 1. There were no signiﬁcant
differences in baseline patient characteristics, including age,
gender, race, diagnosis at transplantation, disease risk status
[34], degree of donor HLA match, CMV serostatus, condi-
tioning regimen, donor CD34þ cells infused, or GVHD pro-
phylaxis, between the control cohort and study patients. The
incidence of infection events in the ﬁrst 180 days after grade
1 GVHD diagnosis also was not different between the 2
groups (Table 2).
As expected, the median time from HSCT to the onset of
grade 1 acute GVHD did not differ between the control
cohort and study patients (32 versus 28 days, respectively)
(Table 1). However, control patients progressed to grade 2 to
4 acute GVHD sooner than the study patients, with a median
time of 7 days from grade 1 diagnosis to progression,
compared with 24 days in study patients (P ¼ .08) (Table 1).
Forty-three percent of control patients (n¼ 12) progressed to
grade 2 to 4 acute GVHD and required systemic corticoste-
roid therapy within 28 days of grade 1 GVHD diagnosis,
compared with 29% of study patients. The cumulative inci-
dence of grade 2 to 4 GVHD was higher in the control cohort
compared with study patients (61% versus 41%, P ¼ .08)
(Figure 3A) at 1 year. Control patients also experienced a
signiﬁcantly higher incidence of severe grade 3 to 4 acute
GVHD at 1 year (18% versus 3%, P ¼ .05) (Figure 3B). The
cumulative incidence of chronic GVHD did not signiﬁcantly
differ between the 2 groups (P ¼ .40; Figure 3C).
The cumulative incidence of relapse at 2 years in the
control cohort was 41%, with a median time from HSCT to
relapse of 95 days (range, 28 to 833 days). NRM was 15% at
2 years and was caused by GVHD-related complications
(n ¼ 5) and an acute hemorrhagic event (n ¼ 1). The overall
survival of the control cohort was 56% at 2 years. These were
not different from the study patients, who had incidences of
relapse, NRM, and survival of 32%, 19% and 63%, respectively.
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Figure 3. Incidence of GVHD in study (n ¼ 34) and contemporaneous control
(n ¼ 26) patients. (A) Cumulative incidence of grade 2 to 4 acute GVHD. Study
versus control, P ¼ .08. (B) Cumulative incidence of grade 3 to 4 acute GVHD.
Study versus control, P ¼ .05. (C) Cumulative incidence of moderate-to-severe
chronic GVHD. Study versus control, P ¼ .40. Dashed line, contemporaneous
control patients; solid line, study patients treated with etanercept.
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Recently, biomarkers with relevance for GVHD have been
identiﬁed using proteomics discovery and validation strate-
gies [29-31,35-37] and may provide opportunity for early
intervention and improved survival after HSCT [36]. These
include elaﬁn and Reg3a as skin-speciﬁc [31] and GI-speciﬁc
[30,35] biomarkers of acute GVHD, respectively, and ST2 as a
predictor for therapy-resistant GVHD and death without
relapse [29]. Although the small sample size in this study
precluded the ability to predict later outcomes, such as NRM
and OS, we measured the concentrations of ST2, Reg3a, and
elaﬁn in the plasma of study patients at the time of grade 1
acute GVHD diagnosis (day 0, before etanercept onset), as
well as 14 and 28 days later. Findings were compared be-
tween study patients and contemporaneous control patients
who did not get etanercept. ST2 and Reg3awere detectable in
the plasma of study patients on day 0 and remained un-
changed on day 28 (Figure 4A,B; left panels). In contrast, ST2
levels in the control cohort progressively increased between
diagnosis and day 28 (medians, 19.2 to 46.6 ng/mL; P ¼ .004)
(Figure 4A). Reg3a also increased more than 2-fold in the
controls, from a median concentration of 8.6 ng/mL at diag-
nosis to 19.6 ng/mL on day 28 (P ¼ .005) (Figure 4B). We
compared the magnitude of change in ST2 and Reg3a con-
centrations in the ﬁrst 28 days between study patients and
contemporaneous controls by normalizing day 28 levels to
day 0 levels (ie, ratio of day 28 over day 0 concentration) for
each patient. Study patients experienced smaller increases in
ST2 (medians, 1.3-fold versus 2.0-fold; P ¼ .06) and Reg3a
levels (medians, .7-fold versus 1.5-fold; P ¼ .01) than the
control cohort 28 days after grade 1 GVHD diagnosis
(Figure 4C). The levels of elaﬁn also decreased during eta-
nercept treatment fromamedian concentration of 17.8 ng/mL
at diagnosis to 12.2 ng/mL on day 28 (P < .0001) (Figure 4D)
but did not change in contemporaneous control patients who
were not treated with etanercept (data not shown).
In addition to the utility of TNFR1 as a biomarker for acute
GVHD, the protein is also targeted by etanercept treatment.
We, therefore, measured the concentration of TNFR1 in the
plasma of patients to determine whether etanercept reduced
plasma TNFR1 levels over the course of 28 days. We found
that plasma TNFR1 levels in study patients did not differ from
levels in the control cohort at the time of diagnosis (P ¼ .40;
data not shown) but that levels were signiﬁcantly reduced in
study patients by day 28 (P ¼ .01) (Figure 4E).
We also compared biomarker concentrations at each time
point between patients whose grade 1 GVHD progressed to
grade 2 to 4 at any time after HSCTand patients whose GVHD
remained grade 1 or resolved with treatment. Plasma ST2
concentrations were signiﬁcantly higher in both study and
contemporaneous control patients whose GVHD progressed
to grade 2 to 4 compared with patients whose GVHD did not
progress, despite the small sample size of this study
(Figure 5). This difference was evident in the control patients
at the time of grade 1 GVHD diagnosis (day 0, P ¼ .02) and
reached signiﬁcance in study patients on day 14 (P ¼ .002).
There were no signiﬁcant differences in median ST2 con-
centrations between study and control patients at diagnosis
(day 0) or at later time points, when the levels were analyzed
by progression status (all P > .20). Reg3a, elaﬁn, and TNFR1
plasma concentrations were not signiﬁcantly different in
patients whose GVHD progressed to grade 2 to 4 compared
with patients whose GVHD remained grade 1 (data not
shown).
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Figure 5. Patients whose acute GVHD progressed to grade 2 to 4 had higher plasma ST2 levels than patients whose GVHD did not progress. Plasma ST2 concen-
trations at the time of grade 1 diagnosis and treatment onset (day 0), day 14, and day 28 in patients whose GVHD remained grade 1 or resolved with treatment
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Figure 4. Biomarkers of acute GVHD in the plasma of study and contemporaneous control patients. Red circles denote patients in the study who received etanercept
treatment. Blue squares are contemporaneous control patients. Horizontal black lines show the median values on each plot. (A and B) Plasma ST2 and Reg3a
concentrations at the time of grade 1 diagnosis and treatment onset (day 0), day 14, and day 28. (A) Plasma ST2. (B) Plasma Reg3a. (C) Day-28 ST2 (left) and Reg3a
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calculate the normalized value is indicated on each plot. Values plotted using linear-scale y-axis. (D) Plasma elaﬁn. (E) Plasma TNFR1. (A, B, D, E) Study patient samples
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This study reports the clinical outcomes of patients with
newly diagnosed grade 1 (skin stage 1 or 2 only) acute GVHD
who were treated with etanercept in addition to topical
corticosteroids as ﬁrst-line therapy.
The single-arm design and lack of published data on
systemic treatment of grade 1 acute GVHD and its progres-
sion are limitations of this study. We constructed a
contemporaneous control population consisting of patients
who were diagnosed with grade 1 acute GVHD and were
treated with topical corticosteroids but not etanercept at our
institution during the study period to provide a comparator
for our study population, while mitigating potential differ-
ences in clinical practice that might be encountered using
historical controls. Control patients fulﬁlled all study eligi-
bility criteria and were not selected on the basis of clinical
characteristics. Although no signiﬁcant differences between
the study and control groupwere noted (Table 1), bias cannot
be completely excluded, especially in the decision to treat
grade 1 acute GVHD with topical corticosteroids as opposed
to systemic corticosteroids at diagnosis. It is possible that a
decision to treat with topical steroids at the time of diagnosis
was indicative of a clinical opinion that the patient was at
lower risk or that progression of acute GVHD was not an
imminent risk. The small sample size of both the study and
control cohorts also diminishes the ability of statistical
methods to identify small differences in patient de-
mographics. This study was powered based on enrollment of
50 patients over 3 years, but the decision was made to close
the study, solely because of slow accrual after enrolling 34
patients over a 5-year period (2008 to 2013).
Forty-three percent of control patients progressed to
grade 2 to 4 acute GVHD within 28 days of grade 1 diagnosis,
with a median time to progression of 7 days. The 1-year cu-
mulative incidence of grade 2 to 4 and grade 3 to 4 acute
GVHD in these patients was 61% and 18%, respectively. It is
encouraging that during the same time period, 29% of pa-
tients treated with etanercept on our study progressed to
grade 2 to 4 acute GVHD within 28 days of grade 1 diagnosis,
with a median time to progression from grade 1 to grade 2 to
4 acute GVHD of 24 days. Study patients experienced 1-year
cumulative incidence of grade 2 to 4 and grade 3 to 4 acute
GVHD of 41% and 3%, respectively. Importantly, the decrease
in grade 3 to 4 GVHD in study patients was not a consequence
of fewermismatched unrelated HSCT, which carry higher risk
for more severe GVHD, and did not result in increased inci-
dence of relapse in study patients. Etanercept treatment also
did not change the incidence of chronic GVHD in the study
patients compared with patients who did not receive eta-
nercept. Nonetheless, only a prospective randomized trial
can adequately compare outcomes after etanercept treat-
ment with outcomes in the absence of etanercept.
We analyzed biomarkers of acute GVHD in plasma sam-
ples at grade 1 onset as well as 14 and 28 days after initiation
of treatment. These analyses were exploratory and were not
analyzed for associationwith clinical outcomes, such as NRM
and survival, because of the small sample size in this study.
Patients treated with etanercept demonstrated reduced
biomarker levels compared with contemporaneous controls
who did not receive etanercept. These ﬁndings trend with
the clinical ﬁndings that study patients had fewer severe
stage 3 to 4 skin rashes (8 versus 12, respectively) and fewer
manifestations of severe stage 3 to 4 GI GVHD (1 versus 6,
respectively) compared with contemporaneous control pa-
tients. The small sample size of this study and the even lowerfrequency of severe GVHD manifestations in target organs
precluded statistical correlation of biomarker levels with
GVHD at speciﬁc sites (ie, skin and GI). However, when
biomarker concentrations were analyzed according to GVHD
progression status, ST2 levels were signiﬁcantly higher in
study and control patients whose GVHD progressed to grade
2 to 4 at any time after grade 1 diagnosis compared with
patients who did not progress, in accord with the recent
report that ST2 is an independent predictor for therapy
resistant GVHD [29]. That Reg3a, elaﬁn, and TNFR1 levels did
not signiﬁcantly differ in progressors compared with non-
progressors in this study may simply be a result of our small
sample size coupled with a narrow dynamic range of change
in these markers, and also because these biomarkers are
typically assessed as components of a multibiomarker panel,
not as stand-alone indicators [36]. It is important to continue
monitoring these biomarkers in large, randomized studies of
patients to better understand their clinical signiﬁcance and
utility in earlier diagnosis of GVHD, as well as in predicting
which patients will respond to treatment or are at risk for
swift progression to more severe GVHD [29-31,35-39]. Cur-
rent reliance on clinical symptomology alone for GVHD
diagnosis can result in a very short window of opportunity to
treat mild GVHD before it becomes a more severe manifes-
tation, a problem that is compounded by the fact that many
patients, before their grade 1 GVHD diagnosis, are out-
patients and are, thus, only seen in clinic on a weekly basis.
These factors represent signiﬁcant challenges in the study of
grade 1 acute GVHD. Earlier identiﬁcation of the ﬁrst hint of
GVHD may allow more efﬁcacious treatment and delay or
spare altogether the need for systemic steroid therapy by
reducing the progression of acute GVHD [29].
Our ﬁndings suggest that grade 1 acute GVHD is not a
benign process. Diagnosis of grade 1 acute GVHD among
contemporaneous control patients resulted in a 1-year cu-
mulative incidence of grade 2 to 4 acute GVHD of 61%,
despite initiating treatment with topical corticosteroids at
grade 1 diagnosis. However, more effective treatment of
grade 1 GVHD is hindered by a paucity of trials that address
its clinical care. Many groups preemptively treat grade 1
acute GVHD with systemic corticosteroids based on risk
assessment (ie, mismatched, unrelated HSCT) or a clinician’s
best guess of potential for worsening acute GVHD. However,
despite common use, systemic steroid therapy has not
proven to unilaterally beneﬁt this patient population and
carries signiﬁcant risk of infection and relapse secondary to
immunosuppression [9]. Potential long-term complications
associated with prolonged steroid use, such as hypertension,
hyperglycemia, and avascular necrosis, may also impact
quality of life and inﬂuence the economic burden after HSCT.
This trial uniquely studied the ﬁrst-line treatment and
evaluation of grade 1 acute GVHD. Treatment of newly
diagnosed grade 1 acute GVHD with etanercept reduced the
incidence of progression to grade 2 to 4 acute GVHD within
28 days compared with contemporaneous patients who
were treated with topical corticosteroids but did not receive
etanercept. Future prospective studies are needed to better
identify patients with grade 1 acute GVHD who may warrant
therapy to prevent progression tomore severe GVHD, as well
as to provide published clinical outcomes associated with
grade 1 acute GVHD.
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